Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34-selected autologous peripheral blood stem cells
- Development stage
- Unknown
- Lead developer
- University of Pittsburgh
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34-selected autologous peripheral blood stem cells is an investigational cell therapy being evaluated for the treatment of severe, treatment-resistant systemic sclerosis (SSc), including juvenile-onset systemic sclerosis (jSSc). Developed by Dr. Paul Szabolcs at the University of Pittsburgh, the therapy involves the collection of a patient's own hematopoietic stem cells via apheresis following mobilization with G-CSF and cyclophosphamide. These cells are then processed to select for the CD34+ population, which serves to enrich for stem cells while depleting autoreactive T and B lymphocytes that drive the underlying autoimmune pathology. Following a high-dose immunoablative conditioning regimen—which may include agents such as alemtuzumab, rituximab, thiotepa, and total body irradiation—the purified CD34+ cells are reinfused. This process aims to 'reset' the patient's immune system, allowing for the reconstitution of a healthy, non-autoreactive immune repertoire.
- Other names
- CD34-selected PBSCCD-34-selected PBSCCD 34-selected PBSCAutologous hematopoietic stem cell transplantationCD34+ selected autologous peripheral blood stem cells
Beyond the preview
Go deeper on CD34-selected autologous peripheral blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34-selected autologous peripheral blood stem cells.